HIVManagement.org

 
Quick Menu / Table of Contents
Introduction Principles Management NRTI Info NNRTI Info
PI Info Fusion Inhibitors Drug Summary Investigational Adherence
Lab Evaluation Resistance Tests PEP Antiretroviral Tables OI Prevention
Vaccinations TB Therapy Hepatitis Therapy OI Diagnosis OI Therapy
Bibliography Links Palliative Therapy

 

Combivir
zidovudine - lamivudine

Detailed Prescribing Information

July 2006

 

Combivir
A combination of zidovudine + lamivudine
Forms Available 300 mg zidovudine / 150 mg lamivudine in tablets
Dosing 1 tablet twice a day
Renal dosing: not recommended
Hepatic dosing: not recommended
Food dependence This medication is best taken on an empty stomach.
Adverse Effects Same as zidovudine plus lamivudine

Mainly bone marrow suppression (leukopenia, granulocytopenia, megaloblastic anemia,) nausea, headaches due to zidovudine
Rarely mitochondrial toxicity such as myopathy, cardiomyopathy (case reports only), steatosis, or lactic acidosis

Interactions Same as zidovudine plus lamivudine
Suggested lab follow-up Monthly CBC, comprehensive biochemical profile for 3 months, then every 3 months if stable
Check serum lactic acid for symptoms of lactic acidosis (weakness, nausea, muscle aches, anion gap acidosis)
Warning Rare lactic acidosis and hepatic steatosis.
Use cautiously in patients with pre-existing anemia
Possible flare of chronic hepatitis B if Combivir is discontinued suddenly.

Suggested Usage

Do not use in combination with lamivudine, emtricitabine, Truvada, Epzicom, Atripla, or Trizivir due to identical mechanism of action or duplication of lamivudine dosing or action.
Do not use Combivir with stavudine due to antagonism with the zidovudine component of Combivir.
Do not discontinue abruptly in patients with chronic hepatitis B without consideration of continuation of lamivudine or some other agent active against hepatitis B.

Complete prescribing information

http://www.combivir.com

 

Links to Antiretroviral Sections (click on anything)
Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI)
AZT  |  ddC  |  ddI  |  d4T  |  3TC  |  ABC  |  FTC  |  TDF  |  Combivir  |  Trizivir  |  Epzicom  |  Truvada  |  Atripla
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI)
efavirenz  |  nevirapine  |  delavirdine
Protease Inhibitors (PI)  |  Boosted Protease Inhibitors
saquinavir  indinavir  |  ritonavir  |  nelfinavir  |  amprenavir  |  lopinavir + ritonavir  |  atazanavir  |  fosamprenavir  | tipranavir  |  darunavir
Fusion Inhibitors
enfuvirtide
 
Quick Menu / Table of Contents
Introduction Principles Management NRTI Info NNRTI Info
PI Info Fusion Inhibitors Drug Summary Investigational Adherence
Lab Evaluation Resistance Tests PEP Antiretroviral Tables OI Prevention
Vaccinations TB Therapy Hepatitis Therapy OI Diagnosis OI Therapy
Bibliography Links Palliative Therapy

 

Updated 7.14.2006

 


 

1. Renal dosing information from: Ian R. McNicholl & Rudolph A. Rodriguez, MD, Dosing of Antiretroviral Drugs in Renal Insufficiency and Hemodialysis, May 2004
http://hivinsite.ucsf.edu/InSite?page=md-rr-18